ClinicalTrials.gg
CompletedNCT00783393Updated May 15, 2017

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

A Phase 2 interventional study of Temozolomide in Astrocytoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled May 2003, registered Oct 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing temozolomide in Astrocytoma — 5 open to participants now, 9 under way, 4 of them phase 3. Temozolomide · Astrocytoma.

Enrollment
45th of 71
32 · median 53
Started
2003
the only one that year
Phase 2
32 of 82
3 open now
Registered
54th of 82
by date
Lead sponsor
3 of 82
Merck Sharp & Dohme LLC

Among the 82 studies testing temozolomide in Astrocytoma, this one is the 45th largest by enrollment of the 71 interventional ones that give a count, is the only one that started in 2003, is one of 32 in phase 2, and was the 54th registered.

Astrocytoma

688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.

Browse Astrocytoma studies →

Open to participants now

5 of the 82 studies testing temozolomide in Astrocytoma are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 68 Astrocytoma studies recruiting now, 40 (59%) set no upper age limit and 14 (21%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing temozolomide in Astrocytoma, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.

03

Conditions studied

  • Astrocytoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have confirmed anaplastic astrocytoma on the tentorium at first relapse, and satisfy the following:

    • unequivocal evidence of tumor recurrence or aggravation by MRI scan after treatment for initial onset; the lesions must be measurable;
    • anaplastic astrocytoma diagnosed histologically by the last pathological diagnostic tests (including initial diagnosis) prior to initial administration of temozolomide;
    • tissue samples available for Central Pathologic Reviewer;
    • pathologic diagnosis report by the study-conducting medical institution must be available for the sponsor.
  • MRI-related criteria:

    • MRI scan performed within 14 days before initial temozolomide administration;
    • assessable tumor site confirmed by MRI;
    • dosage of steroidal agents not increased within 7 days before MRI prior to initial temozolomide administration, except for postoperative subjects for first relapse;
    • MRI performed at the Principal Investigator's study location or designated radiology facility during the study.
  • Age >=18 years, either sex, inpatients or outpatients.
  • Use of medically approved methods in fertile subjects.
  • performance status >=70.
  • Adequate clinically laboratory values obtained within 14 days before initial temozolomide administration.
  • Criteria regarding treatment of initial onset:

    • tumor , regardless of tumor resection at initial diagnosis;
    • prior radiation therapy;
    • prior chemotherapy with up to one nitrosourea-containing regimen.
  • Tumor may or may not have been surgically resected at first relapse, but residual is required.
  • For subjects who had surgical resection of tumor at first relapse:

    • MRI scan must have been performed within 72 hours after surgery.
    • the dose of steroidal agents must be reduced before temozolomide administration.
  • >=12 weeks.
  • Written obtained.

Exclusion criteria

Exclusion Criteria:

  • History of treatment with dacarbazine.
  • Subjects who received chemotherapy within 6 weeks before initial temozolomide administration.
  • Subjects who received interstitial radiotherapy or stereotactic radiosurgery.
  • Subjects who completed radiotherapy within 12 weeks before initial temozolomide administration.
  • Surgery at first relapse (including ) within 1 week before initial temozolomide administration.
  • Subjects not recovered from acute toxicity due to previous therapy.
  • High-risk subjects with complication of diseases other than malignant tumor, or who require systemic administration of antibiotics for infection.
  • Previous or concurrent at other sites.
  • Pregnant or nursing women.
  • Women of not using an effective method of .
  • Subjects previously treated with temozolomide.
  • Participation in an ongoing clinical study, or in other clinical studies within 6 months before initial temozolomide administration.
  • Subjects found inappropriate for the study by the investigator or subinvestigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Single arm

    The study consists of two steps: * Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and * Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1.

    Drug: Temozolomide

Interventions

  • Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.

    Also known as: Temodal, Temodar, SCH 052365

06

What researchers measure

Primary outcomes

  1. Overall response in Step 1

    Time frame: 6 months

  2. Incidence rate and severity of adverse events with administration of temozolomide in Step 1

    Time frame: 7 months (during temozolomide administration for 6 months and follow-up for 1 month)

Secondary outcomes

  1. Progression-free survival in Step 1

    Time frame: 6 months

  2. Overall survival in Step 1

    Time frame: 6 months

  3. Tumor response in Step 1

    Time frame: 6 months

  4. Neurological improvement in Step 1

    Time frame: 6 months

  5. Progression-free survival, overall survival, overall response, effect on neurological symptoms, and safety in Step 2

    Time frame: 6 months

  6. Progression-free survival in Step 2

    Time frame: Up to 2 years

  7. Overall survival in Step 2

    Time frame: Up to 2 years

  8. Overall response in Step 2

    Time frame: Up to 2 years

  9. Effect on neurological symptoms in Step 2

    Time frame: Up to 2 years

  10. Safety in Step 2

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2003 to primary completion in Jun 2005, 24 months.

Of 51 phase 2 interventional studies under Astrocytoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 100. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
StartActual
May 27, 2003
Primary completionActual
Jun 17, 2005
CompletionActual
Jun 17, 2005
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00783393
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
May 27, 2003
Primary completion
Jun 17, 2005
Completion
Jun 17, 2005
Last update
May 15, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion